T1	HMM 67 124	long-term prognosis of advanced nasopharyngeal carcinoma.
T2	HMM 158 196	safety, efficacy, and 6-year follow-up
T3	HMM 758 787	adverse events and responses.
T4	HMM 796 821	rAd-p53-specific p53 mRNA
T5	HMM 920 936	p21/WAF1 and Bax
T6	HMM 959 993	vascular endothelial growth factor
T7	HMM 1039 1061	Complete response rate
T8	HMM 1263 1301	5-year locoregional tumor control rate
T9	HMM 1374 1440	5-year overall survival rate and 5-year disease-free survival rate
T10	HMM 1583 1623	dose-limiting toxicity or adverse events
T11	HMM 1645 1660	transient fever
T12	HMM 1736 1765	safe and biologically active.
T13	HMM 1810 1858	radiotherapeutic tumor control and survival rate
